PDCD1 and cancer: The SAR study revealed that the phenyl-pyrazolone moiety could provide a new approach in designing PD-L1 blocking agents, which night be useful to effectively overcome cancers and other pathological conditions associated with PD-1/PD-L-1 checkpoint.